Merck & Co (NY:MRK)

Stay informed about the performance of the S&P500 index one hour before the close of the markets on Tuesday. Uncover the top gainers and losers in today's session for valuable insights.

What's going on in today's session: S&P500 movers ↗

September 30, 2025

Via Chartmill

Merck (MRK) Shares Skyrocket, What You Need To Know

September 30, 2025

Shares of global pharmaceutical company Merck (NYSE:MRK) jumped 5.7% in the afternoon session after the company announced positive results from its Phase 3 HYPERION trial for its drug, WINREVAIR™...

Via StockStory

Topics Artificial Intelligence

IO Biotech Stock Plunges After FDA Recommends Another Trial For Investigational Cancer Vaccine ↗

September 29, 2025

Pharmaceutical Tariffs ‘A Light At The End Of The Trump Tunnel’ For Big Pharma, Says Jefferies ↗

September 26, 2025

The global cattle feeding industry is at a critical juncture, facing mounting pressures from volatile feed costs, stringent environmental regulations, and a persistent labor crunch. In response, a wave...

Topics Government

Tech Revolutionizes Cattle Feeding: A Sustainable Future for Livestock Markets

September 30, 2025

Curious about the top performers within the S&P500 index in the middle of the day on Tuesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.

Topics Artificial Intelligence Climate Change Emissions

Discover which S&P500 stocks are making waves on Tuesday. ↗

September 30, 2025

Via Chartmill

Merck's Winrevair Cuts Clinical Worsening Risk By 76% Among Hypertension Patients ↗

September 30, 2025

Merck reported Phase 3 results showing Winrevair significantly reduced clinical worsening in pulmonary arterial hypertension patients.

Via Benzinga

Evaxion Stock Jumps A Whopping 43% Pre-Market – Here’s What Happened ↗

September 25, 2025

WINREVAIR™ (sotatercept-csrk) Reduced the Risk of Clinical Worsening Events by 76% Compared to Placebo in Patients Recently Diagnosed With PAH on Background Therapy in Phase 3 HYPERION Trial

September 30, 2025

From Merck Sharp & Dohme

Via Business Wire

Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes

September 29, 2025

Merus N.V. (NASDAQ: MRUS) has become the undisputed top performer in today's market, with its stock price rocketing by an astounding 35.9% following the bombshell announcement of its acquisition by...

U.S. Government Teeters on Brink of Shutdown: Markets Brace for Uncertainty Amidst Data Blackout Fears

September 29, 2025

As the clock ticks towards the September 30, 2025, funding deadline, the United States federal government finds itself perilously close to another shutdown. Congressional leaders remain deadlocked on a...

Pharma Lobby Announces New Website To Connect Patients With Manufacturer-Direct Purchase Program ↗

Topics Bonds Economy Government

September 29, 2025

The announcement from the group coincides with the deadline set by President Trump for 17 pharmaceutical companies to reduce drug prices in the U.S. to the levels paid by other developed countries.

In a hypothetical scenario playing out just last week, leading up to September 27, 2025, Johnson & Johnson (NYSE: JNJ) experienced a significant stock rally, capturing the attention of investors and...

Topics Government

Johnson & Johnson's Hypothetical Rally: A Look at Potential 2025 Valuation Drivers

September 27, 2025

The healthcare sector experienced a significant downturn on Thursday, September 25, 2025, shedding a notable -1.67% of its value and sending ripples of concern through the broader financial markets....

Topics Economy Intellectual Property

Healthcare Sector Reels: A Deep Dive into Thursday's -1.67% Plunge

September 26, 2025

Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet ↗

Topics Economy

September 26, 2025

Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de

Via Benzinga

Topics Government World Trade

Prediction: 2 Stocks That Will Be Worth More Than BigBear.ai 5 Years From Now ↗

September 26, 2025

BigBear.ai is bigger than both of these AI-focused companies now. That could change.

Robert F. Kennedy Jr. Faces Impeachment Push From Haley Stevens Over 'Health Care Chaos' And Rising Costs: 'Enough Is Enough' ↗

Topics Artificial Intelligence

September 26, 2025

Rep. Haley Stevens (D-Mich.) announced that she will introduce articles of impeachment against Health and Human Services Secretary Robert F. Kennedy Jr.

Via Benzinga

Trump Shocks Pharma With 100% Tariff On Imported Drugs Unless Companies Build In America ↗

September 25, 2025

Moderna Stands By UK As Pharma Giants Criticize Pricing, UK Secures First Onshore mRNA Vaccine Production Centre ↗

Topics Government

September 25, 2025

Moderna, Inc.‘s (NASDAQ: MRNA) UK chief Darius Hughes defended Britain's drug pricing policies after the country was branded the "worst in Europe."

Via Benzinga

Peering Into Merck & Co's Recent Short Interest ↗

September 25, 2025

Merck & Co's (NYSE: MRK) short interest as a percent of float has risen 16.98% since its last report. According to exchange reported data, there are now 27.71 million shares sold short, which is 1.24%...

Via Benzinga

Merck & Co. Inc. (NYSE:MRK): A Prime Candidate for a Dependable Dividend Portfolio ↗

September 25, 2025

Merck & Co. (MRK) offers a solid 3.97% dividend yield with a strong history of growth. Its reliable payout is backed by excellent profitability and a healthy balance sheet, making it a top choice for...

Via Chartmill

United Kingdom The Worst European Country For Drug Prices: Eli Lilly CEO ↗

September 24, 2025

Eli Lilly CEO Dave Ricks criticizes UK drug pricing and rebate rules as pharma giants scale back investments, warning of fewer new medicines.

Via Benzinga

The Smartest Dividend Stock to Buy With $1,000 Right Now ↗

September 24, 2025

Drug makers are out of favor right now, but the industry will survive. Here's one company that stands out as an investment option.

Pfizer has a huge yield right now, but it might make more sense for dividend investors to step down in yield to these two alternatives.

Topics Intellectual Property

Should You Forget Pfizer and Buy These Unstoppable Stocks Instead? ↗

September 24, 2025

All three of these names are not only built to last, they're being rebuilt to thrive for at least a few more decades.

Topics Intellectual Property

3 Dividend Stocks Perfect for Millennial Investors ↗

September 24, 2025

The Magnificent Seven tech giants are now worth $21 trillion—8x more than top health care stocks, echoing dot-com bubble extremes.

Topics Economy Intellectual Property Retirement

The Magnificent 7 Boom Just Triggered A Dot-Com Era Warning ↗

September 23, 2025

Via Benzinga

Trump Advises Parents To Split Vaccines, Delay Hepatitis B Shots Until Age 12: 'This Is Based On What I Feel' ↗

September 22, 2025

President Donald Trump on Monday offered advice on childhood vaccination schedules, encouraging parents to split up certain immunizations and delay certain others, in sharp contradiction to current...

Via Benzinga

Topics Government

Inflation's Lingering Shadow: Long-Term Expectations Rise Amidst Fed Rate Cuts

September 22, 2025

The financial markets are currently navigating a perplexing economic landscape where long-term inflation expectations are on the rise, even as the Federal Reserve initiates interest rate cuts. In...